OverviewSuggest Edit

Generation Bio is a genetic medicines company creating gene therapy utilizing its non-viral gene therapy platform. It combines three technologies: a cell-targeted lipid nanoparticle delivery system (ctLNP), a closed-ended DNA construct (ceDNA), and a high-capacity capsid-free biologics manufacturing process. In addition to its lead liver-targeted programs in hemophilia A and phenylketonuria (PKU), Generation Bio develops gene therapies for patients with diseases of skeletal muscle and the eye.

TypePublic
Founded2016
HQCambridge, US
Websitegenerationbio.com

Latest Updates

Employees (est.) (Apr 2020)85
Job Openings11
Share Price (Aug 2020)$19.8 (-2%)
Cybersecurity ratingAMore

Key People/Management at Generation Bio

Stephen Dipalma

Stephen Dipalma

Interim Chief Financial Officer
Doug Kerr

Doug Kerr

Chief Development Officer
Matthew Stanton

Matthew Stanton

Chief Scientific Officer
Jennifer Elliott

Jennifer Elliott

Chief Legal Officer
Geoff Mcdonough

Geoff Mcdonough

President & Chief Executive Officer
Mark Angelino

Mark Angelino

Founder & Chief Operating Officer
Show more

Generation Bio Office Locations

Generation Bio has an office in Cambridge
Cambridge, US (HQ)
301 Binney St
Show all (1)

Generation Bio Financials and Metrics

Generation Bio Revenue

Market capitalization (10-Aug-2020)

914.6m

Closing stock price (10-Aug-2020)

19.8
Generation Bio's current market capitalization is $914.6 m.
Show all financial metrics

Generation Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Generation Bio Online and Social Media Presence

Embed Graph

Generation Bio News and Updates

Generation Bio to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that management will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, Aug. 1…

Generation Bio shares soar 23% in trading debut

Shares of Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, soared 23% Friday in their trading debut, after the IPO was upsized and priced at $19 a share, the high end of its price range. The company sold 10.5 million shares to raise $199.5 million. The sh…

Generation Bio prices upsized IPO at $19 a share to raise $199.5 million

Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, priced its upsized initial public offering at $19 a share, the high end of its price range. The company sold 10.5 million shares to raise $199.5 million. The shares will starting trading on Nasdaq later Fri…

Generation Bio Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its initial public offering of 10,526,316 shares of its common stock at an initial public offering pri…

Generation Bio upsizes planned IPO and raises price range

Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, upsized its planned initial public offering on Thursday and raised the price range, suggesting strong demand for the deal. The company is now planning to offer 10 million shares priced at $18 to $19 each. T…

Generation Bio to offer 7.4 million shares in planned IPO, priced at $16 to $18 each

Generation Bio Co. set terms for its planned initial public offering on Monday, with plans to offer 7.4 million shares priced at $16 to $18 each. The company would raise $133.2 million at the top end of that range. The company has applied to list on Nasdaq, under the ticker symbol "GBIO." J.P. Morg…
Show more

Generation Bio Blogs

Generation Bio Frequently Asked Questions

  • When was Generation Bio founded?

    Generation Bio was founded in 2016.

  • Who are Generation Bio key executives?

    Generation Bio's key executives are Stephen Dipalma, Doug Kerr and Matthew Stanton.

  • How many employees does Generation Bio have?

    Generation Bio has 85 employees.

  • Who are Generation Bio competitors?

    Competitors of Generation Bio include X-Chem, GeneQuine Biotherapeutics and IntraBio.

  • Where is Generation Bio headquarters?

    Generation Bio headquarters is located at 301 Binney St, Cambridge.

  • Where are Generation Bio offices?

    Generation Bio has an office in Cambridge.

  • How many offices does Generation Bio have?

    Generation Bio has 1 office.